Ipsen Announces Leadership Changes in Executive Committee
Ipsen, a renowned global biopharmaceutical company, has made pivotal changes to its Executive Committee, aimed at enhancing its direction in specialty care. These changes come as an addition to the dynamic leadership team, with the announcement made recently by the company headquarters.
New Executives Take the Helm
Three key appointments mark significant advancements for Ipsen, as Mari Scheiffele, Andreas Gerber, and Caroline Sitbon take on pivotal roles. Effective September 1, these leaders will be instrumental in steering Ipsen towards innovative development and enhancing its global operations.
Mari Scheiffele - Chief Product Officer
Mari Scheiffele transitions to the role of EVP, Chief Product Officer. With a successful track record leading commercial operations for the International Region over the past four years, Mari will now focus on expanding Ipsen's oncology and rare disease medicines portfolio. Her leadership will be vital in driving product development and enhancing pipeline innovation, succeeding Bartek Bednarz, who will now lead the newly formed Asia, Pacific & China region.
Andreas Gerber - Head of International
Joining Ipsen from Johnson & Johnson, Andreas Gerber takes on the role of EVP, Head of International. His extensive expertise as the former Vice-President in the Oncology Franchise positions him to effectively lead Ipsen's operations across all regions, excluding North America. His focus will be on driving growth within Ipsen’s therapeutic areas: Oncology, Rare Disease, and Neuroscience.
Caroline Sitbon - General Counsel
Caroline Sitbon has been elevated to the role of General Counsel after her successful stint as Senior Vice President, Legal Affairs. Taking over from François Garnier, Caroline will manage legal and business ethics, ensuring compliance and integrity at Ipsen while also serving as the Board's General Secretary.
A Focus on Growth and Impact
David Loew, the Chief Executive Officer of Ipsen, expressed his enthusiasm regarding these appointments, emphasizing the blend of internal promotions and external talents that enhance their leadership. David noted his confidence in each leader’s abilities to contribute positively to Ipsen's ongoing transformation and success. “I am thrilled to welcome Andreas to Ipsen, as I believe his leadership will play a significant role in our growth in international markets,” he shared.
Commitment to Innovation and Patient Care
Mari Scheiffele shared her excitement about taking on the Chief Product Officer role, stating, “I am honored to step into this position and remain committed to fostering innovation that impacts our customers and patients.” Similarly, Andreas Gerber expressed enthusiasm about working alongside a talented team to advance Ipsen's innovative medications and promote access for patients globally.
Caroline Sitbon echoed her commitment to leading a dedicated team in maintaining Ipsen’s high standards of compliance and ethics, stating, “It’s a privilege to be part of Ipsen's mission to advance science for patients.”
About Ipsen
Ipsen is recognized for its strong dedication to developing transformative medicines in the areas of Oncology, Rare Disease, and Neuroscience. With a strategic focus on innovation, Ipsen's efforts are bolstered by nearly a century of development experience and an extensive global network spanning over 40 countries.
With products reaching patients in more than 80 countries, Ipsen remains committed to innovation and excellence in biopharmaceuticals. The company is listed on the Euronext under the ticker, Paris: IPN, and offers a Sponsored Level I American Depositary Receipt (ADR: IPSEY).
Frequently Asked Questions
What are the recent changes to Ipsen's Executive Committee?
Ipsen has appointed Mari Scheiffele as Chief Product Officer, Andreas Gerber as Head of International, and Caroline Sitbon as General Counsel.
When will the new executive leaders start their roles?
The new appointments will take effect beginning September 1, 2025.
What sectors does Ipsen operate in?
Ipsen focuses on three main therapeutic areas: Oncology, Rare Disease, and Neuroscience, striving for innovation in each.
Who is the CEO of Ipsen?
David Loew serves as the Chief Executive Officer of Ipsen, overseeing the company’s strategic direction and leadership.
How does Ipsen ensure its medicines reach global markets?
With teams in over 40 countries and strong partnerships worldwide, Ipsen is dedicated to ensuring their transformative therapies are accessible to patients globally.
